Rosenstiel Medical Science Bldg 6160 (R189)
Kerry L. Burnstein, Ph.D.
- Associate Director for Education and Training
- Molecular and Cellular Pharmacology
Dr. Burnstein’s lab studies androgen receptor (AR) signaling pathways that may be exploited therapeutically for the incurable stage of prostate cancer, castration-resistance (CRPC). They seek to understand the mechanisms by which AR and its constitutively active variants regulate genes and gene networks that contribute to cancer progression. The Burnstein lab identifies downstream targets that may be inhibited pharmacologically and test compounds in robust preclinical models that faithfully recapitulate features of human PC from androgen dependence to metastatic castration resistance.